Table 3.

Clinical characteristics of the six patients without pre-emptive nucleot(s)ide treatment

Patient no	Age (years)	Sex	Baseline HBsAg (IU/mL)	Baseline HBV DNA (IU/mL)	Baseline AFP (ng/mL)	ICI ±TKI therapy	FU HBsAg (IU/mL)	FU HBV DNA (IU/mL)	FU AFP at BR (ng/mL)	Peak ALT (U/L)	Peak t.bili (mg/dL)	Rescue NUCs	Death caused by HBV	Best Tumor response to ICI
N1	40.9	M	26.4	35 900	2719.2	Nivolumab	2.01	1280	2799.9	85	0.63	–	None	PD
N2	66.5	F	27.8	252	1859.3	Nivolumab	58.2	26	4974.5	202	5.23	–	None	PD
N3	49.2	M	559.8	8960	1148415.8	Nivolumab	Missing	168 000	544 176.1	174	19.75	TDF	None	PD
N4	40.1	F	1856.77	777	1076.2	Nivolumab Lenvatinib	Missing	70	179.2	46	0.52	–	None	CR
N5	63.9	M	557.88	<20	3445.2	Nivolumab Regorafenib	Missing	<20	8905.3	37	2.77	–	None	PD
N6	64.1	M	0	392	129 258.1	Nivolumab	Missing	Missing	76 472.3	26	9.49	–	None	PD

AFP, alpha-fetoprotein; ALT, alanine aminotransferase; BR, best response; F, female; HBsAg, HBV surface antigen; HBV, hepatitis B virus; ICI, immune checkpoint inhibitor; M, male; NUCs, nucleos(t)ide analogs; T.bili, total bilirubin; TDF, tenofovir disoproxil fumarate; TKI, tyrosine kinase inhibitor.